Elotuzumab, lenalidomide, and dexamethasone in RRMM: final...

Blood Cancer Journal 2020 / 09 Vol. 10; Iss. 9

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Weisel, Katja, San-Miguel, Jesus, Shpilberg, Ofer, Grosicki, Sebastian, Špička, Ivan, Walter-Croneck, Adam, Magen, Hila, Mat
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
10
Journal:
Blood Cancer Journal
DOI:
10.1038/s41408-020-00357-4
Date:
September, 2020
File:
PDF, 810 KB
2020
Conversion to is in progress
Conversion to is failed